ReviewJournal of Alzheimer's disease : JAD2022

Spillover: The Approval of New Medications for Alzheimer's Disease Dementia Will Impact Biomarker Disclosure Among Asymptomatic Research Participants.

Jessica Mozersky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.